Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03164980
Other study ID # NOGGO S16/COMPASS
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date November 27, 2017
Est. completion date August 8, 2023

Study information

Verified date April 2022
Source North Eastern German Society of Gynaecological Oncology
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter, randomized, controlled, open-label study including patients with recurrent, platinum-sensitive, ovarian, peritoneal or fallopian tube cancer. The main scope of the trial is to evaluate QoL during chemotherapy comparing trabectedin/PLD with other standard platinum-based chemotherapy in platinum-sensitive disease.


Description:

This is a multicenter, randomized, controlled, open-label study including patients with recurrent, platinum-sensitive, ovarian, peritoneal or fallopian tube cancer. The main scope of the trial is to evaluate QoL during chemotherapy comparing trabectedin/PLD with other standard platinum-based chemotherapy in platinum-sensitive disease. Patients with recurrent, platinum-sensitive, ovarian, fallopian tube and peritoneal cancer will be stratified according to surgery for relapse (R0 vs. R1/2 resection) vs. no surgery in the same setting and age (< 75 years vs. ≥ 75 years), and randomized 1:1 to receive either trabectedin/PLD (Arm A) or one of 3 platinum-based standard therapies without bevacizumab (Arm B, "other standard therapy"). In case of randomization to "other standard therapy", the investigator has the choice between carboplatin/PLD, carboplatin/gemcitabine and carboplatin/paclitaxel. Patients in both treatment arms will receive chemotherapy up for 6 cycles or until disease progression (PD), unacceptable toxicities or patient's wish to stop therapy, whichever occurs first.


Recruitment information / eligibility

Status Completed
Enrollment 89
Est. completion date August 8, 2023
Est. primary completion date August 8, 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion criteria 1. Women aged = 18 years 2. Patients with histologically confirmed diagnosis of epithelial ovarian cancer, primary peritoneal carcinoma or fallopian tube cancer who received =1 prior chemotherapy 3. Patients must be eligible for platin-containing therapy; Patient is defined as platin-sensitive when considered for platin-containing therapy by the investigator. The time frame from end of prior therapy until disease progression alone is not pivotal for study participation. Patients without a platin-containing regimen in the previous line who are also eligible for platin-containing regime are also appropriate for participation 4. Eastern Cooperative Oncology Group (ECOG) performance status of = 2 5. Adequate baseline organ function as defined as - Leucocytes > 3.0 x 109/l - Platelet count > 100 x 109/l - Absolute neutrophil count (ANC) =1500/mm3 - Haemoglobin = 9 g/dl - Alkaline Phosphatase (AP) = 2.5 × ULN (consider hepatic isoenzymes 5 nucleotidase or gamma glutamyl transpeptidase (GGT), if the elevation could be osseous in origin) - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.5 × ULN - Creatinine-Clearance = 60 ml/min (MDRD formula or Cockroft & Gault formula) - Serum creatinine = 1.5 mg/dl - Creatine phosphokinase (CPK) = 2.5 × ULN - Total bilirubin < ULN 6. Women of childbearing potential should use contraceptives or abstain from heterosexual activity for the course of the study through 6 months after the last dose of study medication or be surgically sterile. 7. Adequate cardiac function defined as left ventricular ejection fraction (LVEF) = 50% as determined by echocardiogram 8. Patients must provide written informed consent prior to performance of study specific procedures or assessments, and must be willing to comply with treatment and follow up assessments and procedures. Exclusion criteria 1. Only malignancies, which influence the prognosis 2. Any unstable or serious concurrent condition (e.g. active infection requiring systemic therapy). 3. Chemotherapy or radiation therapy or tumor embolization within 2 weeks prior to the first dose of study drug or planned during study participation. 4. Patients who have refractory disease. Refractory disease is defined if relapse occurs <4 months after beginning of platin-containing therapy. 5. Hypersensitivity to the active substance or to any of the excipients of study drug 6. Findings from ECG and/or assessment of LVEF which indicate an anthracycline-related cardiotoxic process which contradicts administration of liposomal doxorubicin in accordance with the requirements of the SmPC of PLD. 7. Biological therapy, immunotherapy, hormonal therapy or treatment with an investigational agent within 14 days (for bevacizumab, 30 days) prior to the first dose of study drug. 8. Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study 9. Participation in another clinical study with experimental therapy within the 30 days before start of and during treatment. Participation in a non-interventional study should be discussed with sponsor and NC beforehand. 10. Patients in a closed institution according to an authority or court decision (AMG § 40, Abs. 1 No. 4) 11. Patients who are depending on the sponsor/CRO or investigational site as well as on the investigator. 12. Pregnancy or lactation period, or planning to become pregnant within 7 months after the end of treatment.

Study Design


Intervention

Drug:
Trabectidin (Yondelis)
To compare QoL in patients treated with trabectedin/PLD vs. other standard combination therapy of carboplatin/ PLD, carboplatin/ gemcitabine, or carboplatin/ paclitaxel

Locations

Country Name City State
Germany Universitätsklinikum Aachen Aachen
Germany Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum Berlin
Germany Praxis Krebsheilkunde für Frauen Berlin
Germany Sankt Gertrauden-Krankenhaus Berlin
Germany Medizinisches Zentrum Bonn Friedensplatz Bonn
Germany Universitätsklinikum Brandenburg an der Havel Brandenburg an der Havel
Germany Studien GbR Braunschweig Braunschweig
Germany Städtisches Klinikum Dessau Dessau-Roßlau
Germany Frauenklinik Carl Gustav Carus Dresden
Germany Onkologische Schwerpunktpraxis Dresden
Germany Krankenhaus Nordwest gGmbH Frankfurt
Germany Universitätsklinikum Freiburg Freiburg
Germany ZAGO am Helios Klinikum Krefeld Krefeld
Germany Universitätsfrauenklinik Leipzig Leipzig
Germany Universitätsklinik der Johannes Gutenberg-Universität Mainz Mainz
Germany Ruppiner Kliniken GmbH Neuruppin
Germany Sana Klinikum Offenbach Offenbach
Germany Klinikum Südstadt Rostock Rostock
Germany Caritas Klinikum St. Theresia Saarbrücken
Germany Krankenhaus Saarlouis vom DRK Saarlouis
Germany Christliches Klinikum Unna gGmbH Unna

Sponsors (3)

Lead Sponsor Collaborator
North Eastern German Society of Gynaecological Oncology Frankfurter Institut für Klinische Krebsforschung IKF GmbH, PharmaMar

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary observation of change in QoL QoL change from baseline (C1 D1) to after 3 months (± 2 week) or at progression, whichever occurs first. (EORTC QLQ-C30 in combination with EORTC QLQ-ov28) 3 month
Secondary Difference in QoL measured at day one of every treatment cycle, at the end of the treatment and after 6 and 12 month (follow up) (EORTC QLQ-C30 in combination with EORTC QLQ-ov28). 12 month
Secondary Progression-free survival 18 month
Secondary Overall survival 18 month
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05559255 - Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI N/A
Completed NCT06238557 - Prospective Evaluation of Psychological Consequences and Impact on Long-term Quality of Life
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT05472935 - Asynchronous Mindfulness Based Stress Reduction to Reduce Burnout in Licensed Clinical Social Workers N/A
Recruiting NCT04444544 - Quality of Life and High-Risk Abdominal Cancer Surgery
Completed NCT04281953 - Impact on Quality of Life of Long-term Ototoxicity in Cancer Survivors
Recruiting NCT05546931 - Mobile Health Program for Rural Hypertension N/A
Active, not recruiting NCT04746664 - Effects of Nutrition Counselling on Old Age People's Nutritional Status and Quality of Life in Bahir Dar City, North West Ethiopia N/A
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Recruiting NCT04142827 - The Effect of Long Term Therapy With High Flow Humidification Compared to Usual Care in Patients With Bronchiectasis (BX) N/A
Active, not recruiting NCT05903638 - A Pilot RCT: the Impact of a Virtual MBSR Course on Women With Primary Infertility N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Completed NCT06216015 - Exercise Training and Kidney Transplantation N/A
Completed NCT03813420 - Sleep Quality of Physiotherapy Students Quality of Life and Physical Activity Level N/A
Recruiting NCT05550545 - Infant RSV Infections and Health-related Quality of Life of Families
Completed NCT05346588 - THRIVE Feasibility Trial Phase 3
Recruiting NCT05233020 - Robotic Versus Hybrid Assisted Ventral Hernia Repair N/A
Terminated NCT03304184 - The Role of Biodentine in Class V Dental Lesions on Oral Health Related Quality of Life Phase 3
Completed NCT05063305 - Probiotics, Immunity, Stress, and QofL N/A
Recruiting NCT05380856 - Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction N/A